Keros Therapeutics
KROS
121 hedge funds and large institutions have $1.06B invested in Keros Therapeutics in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 12 closing their positions.
1,467% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $86K
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
45% more capital invested
Capital invested by funds: $731M → $1.06B (+$330M)
34% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 32
13% more funds holding
Funds holding: 107 → 121 (+14)
11.77% more ownership
Funds ownership: 77.26% → 89.03% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$44M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$33.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.1M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$11.1M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$17.7M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$13.4M |
| 3 |
O
OrbiMed
New York
|
-$7.71M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$7.47M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
126
Soleus Capital Management
Greenwich,
Connecticut
| – | -$405K | -12,700 | Closed |
|
127
Allianz Asset Management
Munich,
Germany
| – | -$389K | -12,200 | Closed |
|
128
Schroder Investment Management Group
London,
United Kingdom
| – | -$254K | -7,917 | Closed |
|
129
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
| – | -$223K | -7,000 | Closed |
|
|
TIM
130
Tortoise Investment Management
White Plains,
New York
| – | -$9.95K | -312 | Closed |
|
131
Allspring Global Investments
Charlotte,
North Carolina
| – | -$3.95K | -124 | Closed |
|
132
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$2K | -55 | Closed |
|
|
C
133
Covestor
London,
United Kingdom
| – | +$125 | +4 | +133% |
|
KROS Hedge Fund Activity: Q4 2023 in Review
121 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2023, worth a combined $1.06B — up 45% from $731M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new KROS positions and 12 closed out — a net gain of 15 holders — while 43 added to existing stakes and 32 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $44M. The largest seller was Yiheng Capital Management, exiting entirely with an estimated $17.7M sold.
- 121 institutional investors held Keros Therapeutics (KROS) as of Q4 2023, up from 107 in Q3 2023.
- Funds reported $1.06B of Keros Therapeutics stock for Q4 2023, up 45% quarter-over-quarter.
- 27 funds opened new Keros Therapeutics positions in Q4 2023 and 12 closed out, a net change of +15 holders.
- The largest Keros Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $44M added.
- The largest Keros Therapeutics seller in Q4 2023 was Yiheng Capital Management, an estimated $17.7M sold.
Based on aggregated 13F filings for Q4 2023.